House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Obstetrics & gynaecology

Prevention, diagnosis and treatment of postpartum haemorrhage

WHO / FIGO / ICM · 2025 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

WHO links prevention, objective blood-loss measurement and a coordinated early treatment response to reduce death and severe harm from postpartum haemorrhage. The therapeutic trigger now includes lower blood loss accompanied by haemodynamic abnormality. Prevention and treatment recommendations differ: a drug discouraged for routine prophylaxis may still have a role once haemorrhage occurs.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Prevent anaemia and use an effective prophylactic uterotonic

  • Assess antenatal anaemia with a full blood count, or an on-site haemoglobinometer where a full count is unavailable. Daily pregnancy supplementation uses 30–60 mg elemental iron plus 400 micrograms folic acid. This prevention regimen is not a substitute for assessment and treatment of established anaemia. [1]
  • For confirmed iron-deficiency anaemia during pregnancy, consider IV rather than oral iron when oral treatment cannot be used or tolerated, or correction is urgently needed. Confine use to the second or third trimester when benefit outweighs risk, with staff able to recognize and treat anaphylaxis and monitoring during and for at least 30 minutes after infusion. [1]
  • Use one quality-assured prophylactic uterotonic for every birth. Where several options are available, oxytocin 10 IU IM or IV is preferred. Give it immediately after birth, preferably within one minute; avoid a rapid IV bolus and use a safe local caesarean-administration protocol. [1]
  • For vaginal birth when IV access already exists, prefer diluted oxytocin 10 IU given slowly over 1–2 minutes to IM administration. Do not place IV access solely to give prophylactic oxytocin routinely; this vaginal-birth recommendation is not a universal caesarean bolus regimen. [1]
  • If a reliable oxytocin cold chain cannot be maintained, use heat-stable carbetocin 100 micrograms IM/IV; if unavailable, oral misoprostol 400 or 600 micrograms is an alternative. Where skilled personnel cannot administer injections, trained community or lay workers can give oral misoprostol; antenatal self-administration distribution requires targeted monitoring and evaluation. [1]
  • Do not routinely use ergometrine/methylergometrine, oxytocin–ergometrine combinations or injectable prostaglandins for PPH prevention. Tranexamic acid is not recommended for routine prevention at vaginal or caesarean birth; it remains a treatment for diagnosed haemorrhage. [1]
  • Avoid routine episiotomy in spontaneous vaginal birth. Controlled cord traction for vaginal birth requires a skilled attendant and agreement that its modest benefits matter; do not use it without a skilled attendant. Do not clamp before one minute unless an asphyxiated newborn must be moved immediately for resuscitation. [1]

Measure blood loss and trigger treatment promptly

  • Objectively measure postpartum blood loss at every birth, using a calibrated drape where appropriate for vaginal birth, and assess uterine tone for early atony. Sustained uterine massage is not needed for prevention after prophylactic oxytocin; therapeutic massage is a different intervention. [1]
  • Start first-response treatment when measured loss reaches at least 300 mL with any abnormal haemodynamic sign, OR at least 500 mL, whichever occurs first within 24 hours of birth. The qualifying signs are pulse above 100/min, shock index above 1, systolic pressure below 100 mmHg or diastolic pressure below 60 mmHg; be especially vigilant in the first 2 hours. [1]
  • These thresholds guide early treatment and referral, not an automatic decision for surgery or advanced intervention. Continue monitoring for concealed as well as visible loss through the first day and use clinical judgement for escalation. [1]
  • For PPH after vaginal birth, rapidly deliver the first-response bundle: uterine massage, an oxytocic medicine, IV tranexamic acid, IV fluids, genital-tract examination and escalation. Ideally start every available component within 15 minutes of diagnosis rather than waiting to complete one before arranging the others. [1]

Use treatment drugs with their timing and route safeguards

  • IV oxytocin is the first-line uterotonic for PPH even if prophylactic oxytocin was already given. Avoid rapid IV injection; use a diluted slow dose and, when needed, a titrated maintenance infusion under the local haemorrhage protocol, monitoring bleeding, tone and haemodynamics. [1]
  • If IV oxytocin is unavailable or ineffective, select another appropriate uterotonic according to contraindications and availability; options include IV ergometrine, an oxytocin–ergometrine combination or a prostaglandin, including misoprostol 800 micrograms sublingually. Do not treat these options as interchangeable in patients with contraindications or retained placenta. [1]
  • Adding misoprostol simultaneously to oxytocin offers no additional treatment benefit. If misoprostol was used for prevention, evidence is insufficient to guide repeat treatment dosing and toxicity must be weighed. Repeated carbetocin for treatment after prophylactic carbetocin is discouraged until better evidence is available. [1]
  • For PPH after vaginal or caesarean birth, give IV tranexamic acid as soon as possible and start within 3 hours of birth. Give 1 g over 10 minutes; repeat 1 g if bleeding continues after 30 minutes or restarts within 24 hours after completing the first dose. The clock starts at birth, not at diagnosis. [1]
  • Do not delay tranexamic acid while confirming the bleeding source: it applies to traumatic and other PPH causes. Avoid it with a clear antifibrinolytic contraindication, such as a known thromboembolic event during pregnancy. The recommendation supports IV use and does not support initiating TXA beyond 3 hours after birth. [1]
  • Prefer isotonic crystalloids to colloids for fluid resuscitation while controlling the bleeding. Examine for genital-tract tears or haematomas, uterine atony and retained placental tissue; persisting bleeding despite the bundle requires prompt senior or higher-level escalation. [1]

Treat retained placenta without delaying definitive care

  • Use a uterotonic specifically for retained placenta after vaginal birth only when PPH is present. Without bleeding, do not routinely give it solely to expel the placenta. If the placenta remains undelivered after 30 minutes without PPH, begin preparations for manual removal; monitor closely rather than applying this interval to active haemorrhage. [1]
  • Provide antibiotic prophylaxis for manual placental removal, including uterine manipulation to remove tissue or explore for retained fragments. Select the regimen according to local organisms, allergy and availability, and retain hand hygiene and aseptic technique. [1]

Escalate persistent bleeding with appropriate facilities

  • For uterine atony after vaginal birth, bimanual uterine or external aortic compression can temporarily control bleeding while definitive care is arranged. A non-pneumatic anti-shock garment is another temporary measure; none replaces definitive haemorrhage control. [1]
  • Consider uterine balloon tamponade for atonic PPH after vaginal birth unresponsive to first-line care ONLY with immediate surgical and blood-product backup, a functioning first-line protocol, reasonable exclusion of trauma or retained tissue, trained staff and adequate monitoring. Do not generalize this recommendation to settings lacking these safeguards. [1]
  • Do not use uterine gauze packing, including haemostatic-agent gauze, for PPH. If conservative measures fail, proceed to surgical control; uterine-artery embolization is an option for refractory atony when resources permit. Cell salvage and umbilical-vein oxytocin for retained placenta remain research-context recommendations. [1]
  • Base blood-product transfusion on ongoing clinical and haematological assessment with a local protocol. A normal early haemoglobin can be falsely reassuring during acute blood loss; do not wait for an isolated threshold when instability and ongoing bleeding require transfusion. Facilities with blood banking should have a massive-transfusion protocol. [1]

Support recovery and make the response reproducible

  • After birth, use IV iron for likely iron-deficiency anaemia when oral iron is unusable or intolerable, or severe anaemia needs rapid correction, with anaphylaxis-capable staff. Inflammation makes ferritin unreliable soon after delivery. IV iron does not replace transfusion when transfusion is clinically indicated. [1]
  • Use facility prevention, diagnosis, treatment and referral protocols, simulation training and audit of prophylactic uterotonic use. Oral iron for 6–12 weeks postpartum may be offered in settings where gestational anaemia is a public-health concern. [1]

Limitations and use

  • This summary preserves core prevention, early response and escalation decisions but does not reproduce every supporting remark, uterotonic contraindication, surgical technique, antibiotic regimen or blood-component replacement target. Use a complete local obstetric-haemorrhage protocol alongside it.
  • The evidence for the coordinated first-response bundle and balloon-tamponade pathway is primarily from vaginal births. Individual treatment recommendations may also apply after caesarean birth, but procedural and dosing protocols must account for that setting.
  • Ferritin thresholds, platelet-transfusion targets and detailed blood-component replacement schedules are outside this summary; use the complete local obstetric-haemorrhage protocol for these decisions.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Prevention, diagnosis and treatment of postpartum haemorrhage

    Selected recommendation material consulted

Original guideline

Publication details

Issuing organisation
WHO / FIGO / ICM
First published
5 October 2025
Resource type
Clinical guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Prevent anaemia and use an effective prophylactic uterotonic
  • Measure blood loss and trigger treatment promptly
  • Use treatment drugs with their timing and route safeguards
  • Treat retained placenta without delaying definitive care
  • Escalate persistent bleeding with appropriate facilities
  • Support recovery and make the response reproducible
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House